Patents Expiring in December 2041
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-007 | Jul 28, 2023 | RX | Yes | Yes | 12,295,987 | ⤷ Get Started Free | TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE | ||||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-007 | Jul 28, 2023 | RX | Yes | Yes | 12,295,987 | ⤷ Get Started Free | TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE | ||||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-008 | Jul 28, 2023 | RX | Yes | Yes | 12,295,987 | ⤷ Get Started Free | TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE | ||||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-008 | Jul 28, 2023 | RX | Yes | Yes | 12,295,987 | ⤷ Get Started Free | TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE | ||||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-009 | Jul 28, 2023 | RX | Yes | Yes | 12,295,987 | ⤷ Get Started Free | TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
